The HIV and AIDS Malignancy Branch (HAMB), which was founded in October 1996, conducts laboratory and clinical research in AIDS-related malignancies, HIV disease, viral-induced tumors, and related diseases. The mission of HAMB is to understand the pathogenesis of these diseases and to develop novel therapies for them based on this understanding. HAMB research is translational and is comprised of an integrated laboratory and clinical effort. Laboratory research is focused on developing and studying new therapies for HIV infection, on the tumors that cause HIV-associated malignancies, and on developing novel therapies for HIV-associated cancers. Clinical research is currently directed towards AIDS-related malignancies.
Investigators in the branch have previously made substantial contributions to the development of AIDS therapies including zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), and daurunavir, and therapies for Kaposi sarcoma including paclitaxel. Ongoing laboratory projects related to HIV include studies of the resistance to anti-HIV drugs, efforts to develop novel anti-HIV drugs and a program to develop novel anti-AIDS drugs with a focus on protease inhibitors that are effective against resistant HIV. HAMB investigators also conduct a number of studies of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8), including the role of KSHV-encoded microRNAs and their effect on cellular genes; the activation of KSHV lytic replication and specific KSHV genes; and the pathogenesis of KSHV-associated tumors and diseases. HAMB has an active clinical program that is studying and developing improved therapies for KSHV-associated tumors (Kaposi sarcoma, multicentric Castleman disease (MCD), and primary effusion lymphoma), as well as other HIV-associated tumors including primary central nervous system lymphoma and anal cancer. HAMB researchers are also investigating KSHV-inflammatory cytokine syndrome (KICS), a disease related to MCD that is also caused by KSHV.
-
Phase I/II of NHS-IL12 Monotherapy and in Combination with M7824 in Advanced Kaposi Sarcoma
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0061Investigator Ramya Ramaswami, M.B.B.S., M.P.H. -
Molecular Characterization of Viral-associated Tumors, Tumors occurring in the Setting of HIV or other Immune Disorders and Castleman Disease
Open - RecruitingNCI Protocol ID NCI-17-C-0174Investigator Robert Yarchoan, M.D.Share this trial: Referral ContactsContact Name Phone Number Matthew Lindsley, MPH, MSN, RN 240-760-6071 -
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-16-C-0171Investigator Kathryn A. Lurain, M.D., M.P.H. -
Phase I Study of Pembrolizumab in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Open - RecruitingNCI Protocol ID NCI-16-C-0066Investigator Kathryn A. Lurain, M.D., M.P.H. -
A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi Sarcoma
Open - RecruitingNCI Protocol ID NCI-16-C-0047Investigator Ramya Ramaswami, M.B.B.S., M.P.H. -
Pilot Study of Tocilizumab in Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - associated Multicentric Castleman Disease
Open - RecruitingNCI Protocol ID NCI-11-C-0233Investigator Robert Yarchoan, M.D. -
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
Open - RecruitingNCI Protocol ID NCI-11-C-0220Investigator Robert Yarchoan, M.D. -
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease Activity
Open - RecruitingNCI Protocol ID NCI-04-C-0275Investigator Robert Yarchoan, M.D. -
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-related Pre-malignant Lesions, and/or Cancer
Open - RecruitingNCI Protocol ID NCI-01-C-0038Investigator Robert Yarchoan, M.D.
| Position | Keywords | Contact Name | Contact E-mail | Number of Positions |
|---|---|---|---|---|
| Postdoctoral Fellow - gammaherpesvirus, pathogenesis |
gammaherpesvirus, pathogenesis, oncogenesis, animal models |
Laurie Krug | laurie.krug@nih.gov | 1 |
| Postdoctoral Fellow - viral malignancy, KSHV |
viral malignancy, HIV malignancy, KSHV, gammaherpesvirus |
Robert Yarchoan | robert.yarchoan@nih.gov | 1 |
Dr. Joseph Ziegelbauer receives tenure
Congratulations to Joe Ziegelbauer on his recent tenure appointment!
About
The HIV and AIDS Malignancy Branch (HAMB), which was founded in October 1996, conducts laboratory and clinical research in AIDS-related malignancies, HIV disease, viral-induced tumors, and related diseases. The mission of HAMB is to understand the pathogenesis of these diseases and to develop novel therapies for them based on this understanding. HAMB research is translational and is comprised of an integrated laboratory and clinical effort. Laboratory research is focused on developing and studying new therapies for HIV infection, on the tumors that cause HIV-associated malignancies, and on developing novel therapies for HIV-associated cancers. Clinical research is currently directed towards AIDS-related malignancies.
Investigators in the branch have previously made substantial contributions to the development of AIDS therapies including zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), and daurunavir, and therapies for Kaposi sarcoma including paclitaxel. Ongoing laboratory projects related to HIV include studies of the resistance to anti-HIV drugs, efforts to develop novel anti-HIV drugs and a program to develop novel anti-AIDS drugs with a focus on protease inhibitors that are effective against resistant HIV. HAMB investigators also conduct a number of studies of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8), including the role of KSHV-encoded microRNAs and their effect on cellular genes; the activation of KSHV lytic replication and specific KSHV genes; and the pathogenesis of KSHV-associated tumors and diseases. HAMB has an active clinical program that is studying and developing improved therapies for KSHV-associated tumors (Kaposi sarcoma, multicentric Castleman disease (MCD), and primary effusion lymphoma), as well as other HIV-associated tumors including primary central nervous system lymphoma and anal cancer. HAMB researchers are also investigating KSHV-inflammatory cytokine syndrome (KICS), a disease related to MCD that is also caused by KSHV.
Clinical Trials
-
Phase I/II of NHS-IL12 Monotherapy and in Combination with M7824 in Advanced Kaposi Sarcoma
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0061Investigator Ramya Ramaswami, M.B.B.S., M.P.H. -
Molecular Characterization of Viral-associated Tumors, Tumors occurring in the Setting of HIV or other Immune Disorders and Castleman Disease
Open - RecruitingNCI Protocol ID NCI-17-C-0174Investigator Robert Yarchoan, M.D.Share this trial: Referral ContactsContact Name Phone Number Matthew Lindsley, MPH, MSN, RN 240-760-6071 -
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-16-C-0171Investigator Kathryn A. Lurain, M.D., M.P.H. -
Phase I Study of Pembrolizumab in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Open - RecruitingNCI Protocol ID NCI-16-C-0066Investigator Kathryn A. Lurain, M.D., M.P.H. -
A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi Sarcoma
Open - RecruitingNCI Protocol ID NCI-16-C-0047Investigator Ramya Ramaswami, M.B.B.S., M.P.H. -
Pilot Study of Tocilizumab in Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - associated Multicentric Castleman Disease
Open - RecruitingNCI Protocol ID NCI-11-C-0233Investigator Robert Yarchoan, M.D. -
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
Open - RecruitingNCI Protocol ID NCI-11-C-0220Investigator Robert Yarchoan, M.D. -
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease Activity
Open - RecruitingNCI Protocol ID NCI-04-C-0275Investigator Robert Yarchoan, M.D. -
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-related Pre-malignant Lesions, and/or Cancer
Open - RecruitingNCI Protocol ID NCI-01-C-0038Investigator Robert Yarchoan, M.D.
PI & Key Staff
Positions
| Position | Keywords | Contact Name | Contact E-mail | Number of Positions |
|---|---|---|---|---|
| Postdoctoral Fellow - gammaherpesvirus, pathogenesis |
gammaherpesvirus, pathogenesis, oncogenesis, animal models |
Laurie Krug | laurie.krug@nih.gov | 1 |
| Postdoctoral Fellow - viral malignancy, KSHV |
viral malignancy, HIV malignancy, KSHV, gammaherpesvirus |
Robert Yarchoan | robert.yarchoan@nih.gov | 1 |
Contact Info
Center for Cancer Research
National Cancer Institute
Bldg. 10, Rm. 6N106, MSC 1868
Bethesda, MD 20892-1868
Ph: 240-858-3250